Format

Send to

Choose Destination
Urol Clin North Am. 2016 May;43(2):247-60. doi: 10.1016/j.ucl.2016.01.011. Epub 2016 Mar 10.

Management of Hypogonadism in Cardiovascular Patients: What Are the Implications of Testosterone Therapy on Cardiovascular Morbidity?

Author information

1
Division of Cardiology, New York University School of Medicine, 462 First Avenue, NBV 17 South, New York, NY 10016, USA.
2
Division of Cardiology, New York University School of Medicine, New York, NY, USA.
3
Division of Cardiology, New York University School of Medicine, New York, NY, USA. Electronic address: howard.weintraub@nyumc.org.

Abstract

Testosterone replacement therapy is recommended for men with clinical androgen deficiency with decades of evidence supporting its use for treatment of sexual, physical, and psychological consequences of male hypogonadism. In this updated review, the authors discuss the implications of testosterone deficiency and conflicting evidence regarding testosterone replacement therapy and its effects on the cardiovascular system. Based on mounting evidence, the authors conclude that testosterone therapy can be safely considered in men with appropriately diagnosed clinical androgen deficiency and concurrent cardiovascular risk factors and even manifest cardiovascular disease after a thorough discussion of potential risks and with guideline-recommended safety monitoring.

KEYWORDS:

Androgen deficiency; Androgens; Cardiovascular risk; Hypogonadism; Mortality; Testosterone

PMID:
27132583
DOI:
10.1016/j.ucl.2016.01.011
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center